How It Works
What are the bottlenecks for MRD and liquid biopsy?
Measurable Residual Disease (MRD, aka Minimal Residual Disease or Microscopic Residual Disease) can be prognostically utilized to predict short- and long-term relapse of both liquid and solid tumors for tumor therapies to increase life span and life quality of cancer patients.
MRD diagnosis using liquid biopsy, however, demands great sensitivity and specificity of NGS based assays. The requirement for the sensitivity for tumor DNA or circulating tumor DNA (ctDNA) that allows for correct MRD detection is high. Furthermore, the low sensitivity of ctDNA MRD monitoring for gene fusions and copy number abnormalities needs to be addressed.
The need for multiomic NGS
Multiomics, such as ctDNA methylation detection when combined with genetic mutation analysis, has demonstrated great promise in tumor-agnostic assays to improve its performance, including specificity, sensitivity, sequencing depth and LOD. But the sample preparation methods that allow for simultaneous detection of both ctDNA methylation profile and mutation profile are still lacking.
How our technologies meet the needs
1. The Accufy NGS tagging library preparation technology (US and global patent pending) for efficient tagging of ctDNA molecules. The Accufy method features the highest ratio of DNA molecules of which both ends are tagged with unique molecular barcodes that can be read by NGS among all the methods available.
2. The Accufy NGS target enrichment technology (US and global patent pending) for selectively enriching target DNA molecules. The Accufy technology is developed to address both the need for operation ease in clinical diagnostic lab and the need to preserve multiomic information of DNA. The Accufy target enrichment process can be performed in as short as 4 hours with performance far superior to current methods including PCR and hybrid capture.
Together, these technologies achieve 1 log improvement of sensitivity to reach 0.001% VAF or better sensitivity thanks to higher efficiency of tagging and multiomic target enrichment.
*: Save Lives through Earlier Detection is a trademark of AccufyDx.
Your Partnership Matters
Save Lives through Earlier Detection Together
The Accufy technologies can save lives! The proprietary NGS tagging library preparation and NGS target enrichment technologies revolutionize the MRD analysis on liquid biopsy samples via NGS in that they feature the greatest sensitivity, short sample prep time and preservation of both epigenetic , RNA and genetic information from the patient blood samples. They can be coupled with existing NGS sample prep or target enrichment technologies. They can also be used as a turnkey solution for multiomic NGS. We would love to hear from you and to partner with you to save lives of many cancer patients.